ANRO Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Benzinga - Mentions: TERN SGML COCO IVVD ...

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

16 days ago - By: Benzinga - Mentions: COCO MASI HPQ TATT ...

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

19 days ago - By: Zacks Investment Research - Mentions: EDIT

Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?

21 days ago - By: Alto Neuroscience, Inc.

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

22 days ago - By: New York Stock Exchange

NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days

23 days ago - By: Zacks Investment Research - Mentions: ASND AUTL IMRX

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

23 days ago - By: Zacks Investment Research

How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99%

a month ago - By: Alto Neuroscience, Inc.

Alto Neuroscience to Participate in Upcoming Investor Conferences

a month ago - By: Zacks Investment Research

Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy

a month ago - By: Zacks Investment Research

Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect?

a month ago - By: Alto Neuroscience, Inc.

Alto Neuroscience Announces $50 Million Private Placement Financing

a month ago - By: Alto Neuroscience, Inc.

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

2 months ago - By: Bragar Eagel & Squire

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2 months ago - By: Stocktwits - Mentions: IWC SCHA

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

2 months ago - By: Alto Neuroscience, Inc.

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

2 months ago - By: Grabar Law Office - Mentions: BCLI FLYW IBTA

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago - By: Robbins LLP

Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit

3 months ago - By: Levi & Korsinsky, LLP

Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

3 months ago - By: Bragar Eagel & Squire

ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline

3 months ago - By: Faruqi & Faruqi, LLP

Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO

3 months ago - By: Faruqi & Faruqi LLP

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

3 months ago - By: THE ROSEN LAW FIRM, P. A.

ANRO Deadline: ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit

3 months ago - By: Bragar Eagel & Squire

ALTO NEUROSCIENCE INC (ANRO) Stock News

ANRO Latest News, Press Relases and Analysis

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99%

Alto Neuroscience to Participate in Upcoming Investor Conferences

Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy

Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect?

Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf

Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit

Shareholders that lost money on Alto Neuroscience, Inc.(ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline

Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

ANRO Deadline: ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit

ANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline